Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

Breast Cancer Clinical Trial

Official title:

Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00974610
• Other study ID #: CTRIAL-IE (ICORG) 07-12
• Secondary ID: CTRIAL-IE (ICORG
• Status: Completed
• Phase: N/A
• First received: September 9, 2009
• Last updated: May 23, 2017
• Start date: August 2008
• Est. completion date: January 2017

Study information

• Verified date: May 2017
• Source: Cancer Trials Ireland
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

Description:

OBJECTIVES:

Primary

• To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups.

Secondary

• To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy.

OUTLINE: This is a multicenter study.

Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 803
• Est. completion date: January 2017
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following advanced metastatic malignancies:

• Malignant melanoma

• Lung cancer

• Breast cancer

• Pancreatic carcinoma

• Colorectal cancer

• Advanced and/or metastatic disease

• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

PRIOR CONCURRENT THERAPY:

• Not specified

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Colorectal Cancer
• Colorectal Neoplasms
• Lung Cancer
• Lung Neoplasms
• Melanoma
• Melanoma (Skin)
• Pancreatic Cancer
• Pancreatic Neoplasms

Locations

Country	Name	City	State
Ireland	Cork University Hospital	Cork
Ireland	Mercy University Hospital	Cork
Ireland	Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital	Dublin
Ireland	Beaumont Hospital	Dublin
Ireland	Mater Misericordiae University Hospital	Dublin
Ireland	Mater Private Hospital	Dublin
Ireland	St Luke's Hospital	Dublin
Ireland	St. James's Hospital	Dublin
Ireland	St. Vincent's University Hospital	Dublin
Ireland	University College Hospital	Galway
Ireland	Letterkenny General Hospital	Letterkenny
Ireland	Mid-Western Cancer Centre at Mid-Western Regional Hospital	Limerick
Ireland	Waterford Regional Hospital	Waterford

Sponsors (1)

Lead Sponsor	Collaborator
Cancer Trials Ireland

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection of peptide and protein markers in serum		Ongoing
Secondary	Identification of the protein/peptide involved		Ongoing